Aurelio Cafaro Selected Research

tat Gene Products (tat Protein)

1/2016	HIV-1 Tat protein vaccination in mice infected with Mycobacterium tuberculosis is safe, immunogenic and reduces bacterial lung pathology.
1/2015	Effects of different routes of administration on the immunogenicity of the Tat protein and a Tat-derived peptide.
4/2009	Containment of infection in tat vaccinated monkeys after rechallenge with a higher dose of SHIV89.6P(cy243).
1/2008	The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: implications for the design of new vaccination strategies against AIDS.
6/2006	Intracellular HIV-1 Tat protein represses constitutive LMP2 transcription increasing proteasome activity by interfering with the binding of IRF-1 to STAT1.
9/2004	Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Aurelio Cafaro Research Topics

Disease

27	Infections 06/2020 - 09/2002
13	Acquired Immunodeficiency Syndrome (AIDS) 01/2015 - 06/2003
5	Disease Progression 08/2019 - 06/2014
5	Viremia 01/2019 - 04/2007
4	HIV Infections (HIV Infection) 01/2022 - 05/2005
4	Virus Diseases (Viral Diseases) 02/2008 - 03/2006
2	Tuberculosis (Tuberculoses) 01/2016 - 09/2006
1	Chronic Disease (Chronic Diseases) 01/2022
1	Reinfection 06/2020
1	Asymptomatic Diseases 06/2016
1	Lentivirus Infections 01/2014
1	Kaposi Sarcoma (Kaposi's Sarcoma) 03/2002

Drug/Important Bio-Agent (IBA)

18	VaccinesIBA 08/2019 - 09/2002
7	AntibodiesIBA 08/2019 - 01/2013
6	Proteins (Proteins, Gene)FDA Link 01/2016 - 09/2004
6	tat Gene Products (tat Protein)IBA 01/2016 - 09/2004
4	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 09/2004
3	Immunoglobulin G (IgG)IBA 01/2016 - 01/2014
3	Antiviral Agents (Antivirals)IBA 01/2014 - 10/2006
2	CytokinesIBA 12/2020 - 01/2014
2	Virulence Factors (Pathogenicity Factors)IBA 01/2015 - 06/2014
2	IntegrinsIBA 06/2014 - 01/2012
2	Pharmaceutical PreparationsIBA 01/2014 - 11/2006
2	AntigensIBA 01/2008 - 09/2002
2	AIDS VaccinesIBA 03/2007 - 11/2006
2	Viral AntigensIBA 11/2006 - 04/2004
1	Therapeutic UsesIBA 06/2020
1	Immunoglobulin M (IgM)IBA 01/2016
1	Immunoglobulin A (IgA)IBA 01/2016
1	InterferonsIBA 01/2016
1	CC ChemokinesIBA 01/2016
1	Trans-Activators (Trans-Acting Factor)IBA 01/2015
1	DefensinsIBA 01/2014
1	Interleukin-10 (Interleukin 10)IBA 01/2014
1	Biomarkers (Surrogate Marker)IBA 01/2014
1	Herpes Simplex Virus VaccinesIBA 01/2014
1	Dihydrotachysterol (AT 10)IBA 09/2010
1	gag Gene Products (gag Protein)IBA 01/2008
1	EpitopesIBA 01/2008
1	Natural Killer Cell ReceptorsIBA 05/2005
1	Interleukin-2 (IL2)IBA 04/2004
1	Interleukin-4 (Interleukin 4)IBA 04/2004
1	Human immunodeficiency virus 1 p16 proteaseIBA 03/2002
1	HIV Protease InhibitorsIBA 03/2002

Therapy/Procedure

5	Highly Active Antiretroviral Therapy (HAART) 01/2022 - 11/2010
1	Microspheres (Microsphere) 01/2014